(Q38109258)

29 August 2017

Developments in external beam radiotherapy for prostate cancer (English)

1 reference

Adaptive radiation therapy

29 August 2017

0 references

1 reference

Nicolaas Lumen

1

1 reference

29 August 2017

Piet Ost

2

1 reference

29 August 2017

Charles Van Praet

3

1 reference

29 August 2017

Gert De Meerleer

4

1 reference

29 August 2017

Geert Villeirs

5

1 reference

29 August 2017

Valérie Fonteyne

6

1 reference

29 August 2017

language of work or name

English

0 references

publication date

21 May 2013

1 reference

29 August 2017

1 reference

29 August 2017

82

1 reference

29 August 2017

1

1 reference

29 August 2017

5-10

1 reference

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

29 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Prostate cancer pain management: EAU guidelines on pain management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Intensity-modulated Radiotherapy With Simultaneous Integrated Boost to Dominant Intraprostatic Lesion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

What dose of external-beam radiation is high enough for prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

What hypofractionated protocols should be tested for prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Acute and Late Toxicity in a Randomized Trial of Conventional Versus Hypofractionated Three-Dimensional Conformal Radiotherapy for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Radiotherapy after prostatectomy: is the evidence for dose escalation out there?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Potential for dose escalation in the postprostatectomy setting with intensity-modulated radiation therapy: a dosimetric study using EORTC consensus guidelines for target volume contours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Improved outcomes with higher doses for salvage radiotherapy after prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Pelvic lymph node dissection in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Pattern of progression and survival in hormonally treated metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Two Positive Nodes Represent a Significant Cut-off Value for Cancer Specific Survival in Patients with Node Positive Prostate Cancer. A New Proposal Based on a Two-Institution Experience on 703 Consecutive N+ Patients Treated with Radical Prostatecto

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

The natural history of noncastrate metastatic prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Is there a favorable subset of patients with prostate cancer who develop oligometastases?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

Stereotactic body radiation therapy: a comprehensive review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.043

10.1016/J.UROLOGY.2013.03.043

7 January 2021

Identifiers

DOI

1 reference

29 August 2017

1 reference